

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

Vinod Chintamani Malshe

Application No.: 10/552,422

Filed: October 7, 2005

Confirmation No.: 6676

For: NOVEL BIODEGRADABLE  
ALIPHATIC POLYESTERS AND  
PHARMACEUTICAL COMPOSITIONS  
AND APPLICATIONS THEREOF

)

) Art Unit: 1615

)

) Examiner: Caralynne E. Helm

)

)

)

)

*I hereby certify that this correspondence is being  
submitted via Electronic Filing System or facsimile (571-  
273-8300) or USPS to the Commissioner for Patents, P.O.  
Box 1450, Alexandria, VA 22313-1450 on:*

)

)

)

)

)

)

)

May 6, 2009

Date of Transmission

Tamara Daw

Name of Person Transmitting Correspondence

*Tamara Daw* 5/6/2009

Signature

Date

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE

Sir:

In response to the Office Action dated March 6, 2008 and the Notice of Non-Compliant Amendment dated August 26, 2008, please enter the following amendments and consider the following remarks.

Amendments to the specification begin on page 2.

Amendment to the claims begins on page 3.

Remarks begin on page 8.

**AMENDMENTS TO THE SPECIFICATION:**

At page 1, lines 1-2 please amend the title as follows:

~~NOVEL~~ BIODEGRADABLE ALIPHATIC POLYESTERS AND PHARMACEUTICAL  
COMPOSITIONS AND APPLICATIONS THEREOF

**IN THE CLAIMS****Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application. Where claims have been amended and/or canceled, such amendments and/or cancellations are done without prejudice and/or waiver and/or disclaimer to the claimed and/or disclosed subject matter, and the applicant and/or Applicant reserves the right to claim this subject matter and/or other disclosed subject matter in a continuing application.

**Listing of Claims:**

What is claimed is:

1. (Currently amended) A pharmaceutical composition, comprising:

at least one pharmaceutically active ingredient; and

poly(ethylene sebacate).

wherein said pharmaceutical composition is in the form of different drug delivery systems, wherein said drug delivery systems comprise one or more of the following structures: drug loaded microparticles, microcapsules, nanoparticles, molded implants, coated granules, films, coated tablets, ophthalmic inserts, fibers, ligatures or sutures

~~Pharmaceutical compositions comprising at least one pharmaceutically active ingredient and biodegradable aliphatic polyesters derived from fatty diacids and fatty diols both with even number of carbon atoms; particularly polyethylene sebacate which is thermally stable, non-toxic, and metabolized by normal lipid metabolism in the form of different drug delivery systems such as drug loaded microparticles, nanoparticles, molded implants, coated granules, injectable sustained release particles, stents, films, matrix tablet, coated tablets, dry syrup, mouth dissolving tablets, microparticles dispersed in gels, taste masked formulation, inserts (ophthalmic), fibers, ligatures and sutures.~~

2. (Currently amended)      The pharmaceutical composition as claimed in claim 1 wherein molecular weight of said poly(ethylene sebacate) is in the range of 3,000 to 30,000The compositions as claimed in claim 1, wherein the molecular weight of said polyethylene sebacate is in the range of 3,000 to 30,000.

3. (Currently amended)      The pharmaceutical composition as claimed in claim 1, wherein said pharmaceutically active ingredient comprises anti-hypertensives, cardiovascular agents, analgesics, steroids, physiologically active peptides and/or proteins, anti-cancer agents, antibiotics, fibrinolytics, anti-inflammatory agents, expectorants, muscle relaxants, epilepsy remedies, anti-ulcerative agents, anti-hyperchondriac agents, anti-allergic agents, diuretics diabetes curatives, hyperlipidemic remedies, anticoagulants, hemolytic agents, anti tubercular agents, hormones, anesthetic antagonists, osteoclastic suppressants, osteogenic promotives, angiogenesis suppressors, mydriatics, myotics, or glaucoma therapy and/or mixtures thereofThe compositions as claimed in claim 1, wherein said pharmaceutically active ingredient is selected from anti-hypertensives, cardiovascular agents, analgesics, steroids, physiologically active peptides and / or proteins, anti-cancer agents, antibiotics, fibrinolytics, anti-inflammatory agents, expectorants, muscle relaxants, epilepsy remedies, anti-ulcerative agents, anti-hyperchondriac agents, anti-allergic agents, diuretics diabetes curatives, hyperlipidemic remedies, anticoagulants, hemolytic agents, anti-tubercular agents, hormones, anesthetic antagonists, osteoclastic suppressants, osteogenic promotives, angiogenesis suppressors, mydriatics, myotics, glaucoma therapy and or mixtures thereof.

4. (Currently amended)      The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutically active ingredient to poly(ethylene sebacate) ratio is in the range from 95:5 to 1:99The compositions as claimed in claim 1, wherein the drug to polymer ratio in said compositions is from 95:5 to 1:99.

5. (Cancelled)

6. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said drug delivery systems comprise molded implants ~~The compositions as claimed in claims 1 to 4, wherein said drug delivery systems are molded implants containing drug.~~

7. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said drug delivery systems comprise coated granules, prepared by coating the granules with 1-5% solution of said poly(ethylene sebacate) in a suitable solvent ~~The compositions as claimed in claims 1 to 4, wherein said drug delivery systems are coated granules, prepared by coating the granules with 1-5% solution of said biodegradable aliphatic polyester in a suitable solvent.~~

8. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said drug delivery systems comprise injectable microparticles suitable for sub-cutaneous, intra-muscular, intravenous or periodontal administration ~~The compositions as claimed in claims 1 to 4, wherein said drug delivery systems are injectable sustained release microparticles suitable for sub-cutaneous, intra-muscular or periodontal administration for sustained action for the required period.~~

9. (Cancelled)

10. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said drug delivery system comprises microparticles and/or nanoparticles dispersed in a gel formulation capable of periodontal administration ~~The compositions in the form of microparticles dispersed in gel as claimed in claims 1 to 4, wherein said drug delivery system in gel form is prepared by incorporating the micro particles in a gel suitable for the treatment of periodontitis.~~

11. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said drug delivery system comprises film ~~The compositions in the form of films as claimed in claims 1 to 4, wherein said drug delivery system is self supporting drug loaded films.~~

12. (Currently amended) The pharmaceutical composition as claimed in claim 1~~The compositions in the form of microcapsule as claimed in claims 1 to 4, wherein said microcapsules comprise~~ [[is ]]sustained release microcapsules.

13. (Currently amended) The pharmaceutical composition as claimed in claim 12~~The compositions as claimed in claim 12, wherein said microcapsules are~~ can be produced in an oil/water suspension system, in which the drug is embedded within the polymer microparticles forming the oil phase, and stabilizing agents for the microparticles forming an the aqueous phase.

14. (Currently amended) The pharmaceutical composition as claimed in claim 13~~The composition as claimed in claim 13, wherein the stabilizing agents comprise~~ are selected from polyvinyl alcohol, polyvinyl pyrrolidone, alginate, gelatin, methyl cellulose, polyoxyethylene derivatives of sorbitan fatty esters and/or polyoxyethylene fatty ethers.

15. (Currently amended) The pharmaceutical composition of claim 1, wherein a particle size of said nanoparticles is in the range of 10 nanometers to 500 nanometers ~~The compositions as claimed in claims 12 to 14, wherein particle size of microparticles is in the range of 10 nm to 1000 microns depending on the type and concentration of stabilizer and drug to polymer ratio used in the formulation.~~

16. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said drug delivery systems comprise lipase capable of modifying release of said pharmaceutically active ingredient ~~The compositions as claimed in claims 1 to 15, wherein said drug delivery systems are with or without the addition of lipase to modify the drug release.~~

17. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said pharmaceutical composition is capable of being administered by either oral, ophthalmic, parenteral, mucosal, or transdermal route ~~The compositions as claimed in claims 1 to 16, wherein said pharmaceutical compositions could be administered by either oral, ophthalmic, parenteral, mucosal or transdermal route.~~

18. (Currently amended)     The pharmaceutical composition as claimed in claim 1, further comprising [[P]]pharmaceutical compositions comprising at least one pharmaceutically active ingredient and biodegradable aliphatic polyesters derived from fatty diacids and fatty diols both with even number of carbon atoms; and particularly polyethylene sebacate which is thermally stable, non-toxic, and metabolized by normal lipid metabolism ~~in the form of different drug delivery systems as substantially described herein with reference to foregoing examples 1 to 18.~~

**REMARKS**

The above-referenced patent application has been reviewed in light of the Office Action and the Notice of Non-Compliant Amendment referenced above. Please enter the following amendments and consider the following remarks.

Reconsideration of the above-referenced patent application in view of the following remarks is respectfully requested.

Claims 1-18 are pending in the application. Claims 1-5, 6-8, and 10-18 have amended and claims 5 and 9 have been cancelled without prejudice. The amendment is fully supported by the disclosure filed on October 7, 2005. No new matter has been introduced.

**Informalities**

Applicant notes that the Examiner crossed out reference FR 2787730A, dated 6/30/2000, which applicant included in an IDS filed on August 14, 2007. Apparently, the Examiner did not consider this reference in the last Office Action mailed March 6, 2008.

**Objection to the Title**

The Examiner has objected to the title and required a new title due to the term "novel".

Accordingly, Applicant has amended the title to remove the term "novel". Applicant respectfully submits that the title is now in proper form.

**Claim objections**

Claims 5-18 have been objected to for being in improper multiple dependent form.



Applicant has cancelled claims 5 and 9 and amended claims 6-8 and 10-18: None of the amended claims comprise multiple dependent form. Accordingly, Applicant respectfully submits that this objection is moot in view of the claim amendments.

**Claim rejections – 35 USC §112**

Claim 1 is rejected under 35 U.S.C. 112 for indefiniteness for use of the term “such as”.

Accordingly, Applicant has amended the title to remove the term “such as”.

Accordingly, Applicant respectfully submits that this objection is moot in view of the claim amendments.

**Claim rejections – 35 USC §102**

Claims 1, 3 and 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Shalaby et al. (U.S. Patent No. 4,186,189).

Applicant respectfully submits the Examiner has not established that the cited references disclose all of the elements of independent claim 1. The Examiner is kindly reminded that the Examiner’s initial burden of factually supporting any *prima facie* case of anticipation requires that the prior art reference must teach every element or limitation of a claim. See MPEP § 2131. For example, Examiner has not established that Shalaby discloses:

... a pharmaceutical composition comprising poly(ethylene sebacate);

as recited in amended claim 1. At page 4 of the present Office Action, the Examiner has characterized Shalaby as follows:

... Shalaby et al. teach a pharmaceutical composition with one or more drugs and the absorbable (biodegradable), aliphatic polyester, poly(alkylene oxalate)...

However, Applicant respectfully submits that the Examiner has not addressed “a *pharmaceutical composition comprising poly(ethylene sebacate)*” as recited in amended claim 1. For at least this reason, Applicant respectfully submits that amended independent claim 1 and dependent claims 2-4, 6-8, and 10-18 are not anticipated or rendered obvious by the cited document. Thus, Applicant respectfully requests that the rejection be withdrawn.

### **Claim rejections – 35 USC §103**

To successfully make a *prima facie* rejection under 35 USC § 103, the Examiner must show that Applicant’s claimed subject matter would have been obvious to one of ordinary skill in the art pertinent to Applicant’s claimed subject matter at the time it was made. See KSR International, Co. v. Teleflex, Inc., 127 S.Ct. 1727 (decided April 30, 2007). Some of the factors to consider in this analysis include the differences between the applied documents and Applicant’s claimed subject matter, along with the level of skill associated with one of ordinary skill in the art pertinent to Applicant’s claimed subject matter at the time it was made. One way in which an Examiner may establish a *prima facie* case of unpatentability under 35 USC § 103 would be to show that three basic criteria have been met. The Examiner, therefore, first, should show that the applied document(s), alone or in combination, disclose or suggest every element of Applicant’s claimed subject matter. Second, the Examiner should show that there is a reasonable expectation of success. Finally, the Examiner should show that there was some suggestion or motivation, either in the applied document(s) themselves or in the knowledge generally available to one of ordinary skill in the art, to, in this case, modify or combine the applied document(s). The motivation or suggestion and the reasonable expectation of success should be found in the prior art, and should not be based on Applicant's disclosure. See In re Vaeck, 947 F.2d 488, 20

USPQ2d 1438 (Fed. Cir. 1991); See MPEP § 2142; 2143 - § 2143.03 (regarding decisions pertinent to each of these criteria). It is respectfully asserted that the Examiner has not met this standard.

Furthermore, on October 10, 2007, the USPTO published in the Federal Register its Examination Guidelines under 35 USC § 103 in view of the KSR decision, cited above. These guidelines contain a number of relevant points. In particular, the new Guidelines state that an Examiner must articulate a reason or rationale to support an obviousness rejection. Specifically, Examiner's must articulate findings as to the scope and content of the prior art to support the obviousness rejection being made. The Examiner should focus on the state of the art and not on impermissible hindsight (e.g., from inappropriate use of Applicant's disclosure). Specifically, Examiners need to account for all claim limitations in the rejections, either by indicating where each limitation is shown by the applied documents or by providing an explanation of how the document is relevant to an obviousness determination despite the limitation not being shown. Thus, Examiners must explain reasoning that provides a nexus between the factual findings and the legal conclusions of obviousness. It is respectfully asserted that the Examiner also has not met these standards.

As discussed above, the applied documents do not provide, inherently or otherwise, all of the elements of the pending claims. Furthermore, the documents applied by the Examiner do not cure this deficiency. For at least these reasons, Applicant respectfully asserts that the Examiner's rejection of the claims is improper.

Claims 1 and 3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shalaby et al.

Applicant respectfully submits that, for the at least the reasons presented above with respect to the rejection of claim 1 under 35 U.S.C. 102, Shalaby fails to teach or suggest all the claim limitations of claim 1. Accordingly, Applicant respectfully submits that claim 1 is not rendered obvious in view of Shalaby and, for at least this reason, respectfully requests withdrawal of the rejection of claim 1 under 35 U.S.C. 103(a).

Claims 3-4, 6-8, and 10-18 are similarly not obvious, at least on the same or similar basis as claim 1. Thus, Applicant respectfully requests withdrawal of this rejection.

Claims 1 and 2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Penhasi (U.S. Publication No. 2003/0208259) in view of Farachi et al. (U.S. Patent No. 6,562,939) and Zhu et al. (Chinese Chemical Letters 2001 12(7):589-592).

Assignee respectfully submits the Examiner has not established that the documents disclose all of the elements of independent claim 1. For example, Examiner has not established that the proposed combination discloses:

*... wherein said pharmaceutical composition is in the form of different drug delivery systems, wherein said drug delivery systems comprise one or more of the following structures: drug loaded microparticles, microcapsules, nanoparticles, molded implants, coated granules, films, coated tablets, ophthalmic inserts, fibers, ligatures or sutures.*

as recited in amended claim 1. At page 6 of the present Office Action, the Examiner points to Penhasi as disclosing use of a stent, stating:

Penhasi teaches a stent with a polymer and drug (see paragraph 22-24; instant claim 1). Specifically Penhasi teaches the drug being incorporated in a polymer matrix where, polyethylene sebacate is taught as one of the preferred polymers (paragraph 35 line 33-34; instant claims 1 and 2).

However, Applicant respectfully submits that the Examiner has not established that the stent of Penhasi shows “*drug delivery systems*” as recited in amended claim 1. More specifically, the Examiner has not established that the stent of Penhasi shows “*drug loaded microparticles, nanoparticles, molded implants, coated granules, films, coated tablets, ophthalmic inserts, fibers, ligatures or sutures*” as recited in amended claim 1. Additionally, Applicant respectfully submits that the Examiner has not established that Farachi and/or Zhu cure Penhasi of this deficiency. In the absence of the Examiner pointing to such a disclosure in the documents, Assignee requests that the rejection be withdrawn as the Examiner failed to establish that the documents render obvious claim 1.

Claim 2 is similarly not obvious, at least on the same or similar basis as claim 1. Thus, Applicant respectfully requests withdrawal of this rejection.

It is noted that claimed subject matter may be patentably distinguished from the cited documents for additional reasons; however, the foregoing is believed to be sufficient. Likewise, it is noted that the Applicant’s failure to comment directly upon any of the positions asserted by the Examiner in the office action does not indicate agreement or acquiescence with those asserted positions.

**Conclusion**

In light of the foregoing, reconsideration and allowance of the claims is hereby earnestly requested.

Any fees or extensions of time believed to be due in connection with this amendment are enclosed herein; however, consider this a request for any extension inadvertently omitted, and charge any additional fees to Deposit Account 50-3130.

**Invitation for a Telephone Interview**

The Examiner is invited to call the undersigned attorney, Brian D. Wichner, at (503) 439-6500 if there remains any issue with allowance.

Respectfully submitted,  
Attorney for Applicant

Dated: May 6, 2009

/Brian D. Wichner/

Brian D. Wichner

Reg. No. 52,359

Customer Number: 43831  
Berkeley Law & Technology Group, LLP  
17933 NW Evergreen Parkway, Suite 250  
Beaverton, OR 97006  
503.439.6500



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/552,422

10/07/2005

Vinod Chintamani Malshe

044-P001

6676

7590 03/17/2009  
Berkeley Law and Technology Group  
1700 N.W. 167th Place, Suite 240  
Beaverton, OR 97006

EXAMINER
----------

HELM, CARALYNNE E

ART UNIT	PAPER NUMBER
----------	--------------

1615

MAIL DATE	DELIVERY MODE
-----------	---------------

03/17/2009

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**Notice of Abandonment**

Application No.

10/552,422

Applicant(s)

MALSHE ET AL.

Examiner

CARALYNNE HELM

Art Unit

1615

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

This application is abandoned in view of:

1. ☒ Applicant's failure to timely file a proper reply to the Office letter mailed on 26 August 2008.
  - (a) ☐ A reply was received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission dated \_\_\_\_\_), which is after the expiration of the period for reply (including a total extension of time of \_\_\_\_\_ month(s)) which expired on \_\_\_\_\_.
  - (b) ☐ A proposed reply was received on \_\_\_\_\_, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection.  
(A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).
  - (c) ☐ A reply was received on \_\_\_\_\_ but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
  - (d) ☒ No reply has been received.
2. ☐ Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85).
  - (a) ☐ The issue fee and publication fee, if applicable, was received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission dated \_\_\_\_\_), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85).
  - (b) ☐ The submitted fee of \$\_\_\_\_\_ is insufficient. A balance of \$\_\_\_\_\_ is due.  
The issue fee required by 37 CFR 1.18 is \$\_\_\_\_\_. The publication fee, if required by 37 CFR 1.18(d), is \$\_\_\_\_\_.
  - (c) ☐ The issue fee and publication fee, if applicable, has not been received.
3. ☐ Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).
  - (a) ☐ Proposed corrected drawings were received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission dated \_\_\_\_\_), which is after the expiration of the period for reply.
  - (b) ☐ No corrected drawings have been received.
4. ☐ The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.
5. ☐ The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.
6. ☐ The decision by the Board of Patent Appeals and Interference rendered on \_\_\_\_\_ and because the period for seeking court review of the decision has expired and there are no allowed claims.
7. ☒ The reason(s) below:

The last correspondence from the Office was returned as undeliverable due to address change not being filed appropriately in application. Applicant's representative was telephoned and notified of issue.

/Caralynne Helm/  
Examiner, Art Unit 1615

/Tracy Vivlemore/  
Primary Examiner, Art Unit 1635

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patent term.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# CHANGE OF CORRESPONDENCE ADDRESS *Application*

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Application Number	10/552,422
Filing Date	October 7, 2005
First Named Inventor	Vinod Maishe
Art Unit	1615
Examiner Name	Caralynne E. Helm
Attorney Docket Number	044.P001

Please change the Correspondence Address for the above-identified patent application to:

☒ The address associated with  
Customer Number:

43831

OR

☐ Firm or  
Individual Name

Address

City

State

Zip

Country

Telephone

Email

This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).

I am the:

- ☐ Applicant/Inventor
- ☐ Assignee of record of the entire interest.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).
- ☒ Attorney or agent of record. Registration Number 52,359
- ☐ Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number \_\_\_\_\_

Signature /Brian D. Wichner, Reg. No. 52,359/

Typed or Printed  
Name Brian D. Wichner

Date

Telephone (503) 439-6500

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☒ \*Total of one forms are submitted.

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4896601
<b>Application Number:</b>	10552422
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6676
<b>Title of Invention:</b>	Biodegradable Aliphatic Polyesters and Pharmaceutical Compositions and Applications Thereof
<b>First Named Inventor/Applicant Name:</b>	Vinod Chintamani Malshe
<b>Correspondence Address:</b>	Berkeley Law and Technology Group - 1700 N. W. 167th Place, Suite 240 - Beaverton OR 97006 US - -
<b>Filer:</b>	Brian D. Wichner/Tamara Daw
<b>Filer Authorized By:</b>	Brian D. Wichner
<b>Attorney Docket Number:</b>	044-P001
<b>Receipt Date:</b>	03-MAR-2009
<b>Filing Date:</b>	07-OCT-2005
<b>Time Stamp:</b>	17:21:41
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Change of Address	044P001ChangeofCorrespAdd. pdf	50286 f91078cb35c82bc073c1cd2f442735a0fc3f8f6d	no	1

**Warnings:**

**Information:**

<b>Total Files Size (in bytes):</b>	50286
-------------------------------------	-------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**


If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/552,422	10/07/2005	Vinod Chintamani Malshe	044-P001	6676

7590 08/26/2008  
Berkeley Law and Technology Group  
1700 N. W. 167th Place, Suite 240  
Beaverton, OR 97006

EXAMINER

HELM, CARALYNNE E

ART UNIT	PAPER NUMBER
----------	--------------

1615

MAIL DATE	DELIVERY MODE
-----------	---------------

08/26/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10552422	10/7/2005	MALSHE ET AL.	044-P001

Berkeley Law and Technology Group  
1700 N. W. 167th Place, Suite 240  
Beaverton, OR 97006

**EXAMINER**

CARALYNNE HELM

**ART UNIT****PAPER**

1615

20080821

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

The timely submission under 37 CFR 1.129(a) filed on June 6, 2008 is not fully responsive to the prior Office action because applicant has made amendments to the incorrect set of claims. The claims pending in the case are those contained in the amendment submitted to the International Bureau on February 4, 2005 and submitted with the 371 application on October 7, 2005.

Since the submission appears to be a *bona fide* attempt to provide a complete reply to the prior Office action, applicant is given a shortened statutory period of ONE MONTH or THIRTY DAYS from the mailing date of this letter, whichever is longer, to submit a complete reply. This shortened statutory period supersedes the time period set in the prior Office action. This time period may be extended pursuant to 37 CFR 1.136(a). If a notice of appeal and the fee set forth in 37 CFR 1.17(e) were filed prior to or with the payment of the fee set forth in 37 CFR 1.17(r), the payment of the fee set forth in 37 CFR 1.17(r) by applicant is construed as a request to dismiss the appeal and to continue prosecution under 37 CFR 1.129(a). The appeal stands dismissed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CARALYNNE HELM whose telephone number is (571)270-3506. The examiner can normally be reached on Monday through Friday 8-5 (EDT).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Caralynne Helm/  
Examiner, Art Unit 1615

/MP WOODWARD/  
Supervisory Patent Examiner, Art Unit 1615

Organization **IC1600** Bldg./Room **REMPSEN**  
UNITED STATES PATENT AND TRADEMARK OFFICE

P.O. Box 1450


Alexandria, VA. 22313-1450

If Undeliverable Return In Ten Days


Official Business

Penalty For Private Use, \$300

AN EQUAL OPPORTUNITY EMPLOYER



02 1M \$ 00.420  
0004244975 AUG 26 2008  
MAILED FROM ZIP CODE 22314




NIXIE 970 DA 1

00 08/29/08

RETURN TO SENDER  
NOT DELIVERABLE AS ADDRESSED  
UNABLE TO FORWARD

BC: 22313145050 \*0217-01302-26-34

97006346531 301190





# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/552,422	10/07/2005	Vinod Chintamani Malshe	044-P001	6676

7590 08/26/2008  
Berkeley Law and Technology Group  
1700 N. W. 167th Place, Suite 240  
Beaverton, OR 97006

EXAMINER
----------

HELM, CARALYNNE E

ART UNIT	PAPER NUMBER
----------	--------------

1615

MAIL DATE	DELIVERY MODE
-----------	---------------

08/26/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10552422	10/7/2005	MALSHE ET AL.	044-P001

Berkeley Law and Technology Group  
1700 N. W. 167th Place, Suite 240  
Beaverton, OR 97006

**EXAMINER**

CARALYNNE HELM

ART UNIT	PAPER
----------	-------

1615 20080821

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

The timely submission under 37 CFR 1.129(a) filed on June 6, 2008 is not fully responsive to the prior Office action because applicant has made amendments to the incorrect set of claims. The claims pending in the case are those contained in the amendment submitted to the International Bureau on February 4, 2005 and submitted with the 371 application on October 7, 2005.

Since the submission appears to be a *bona fide* attempt to provide a complete reply to the prior Office action, applicant is given a shortened statutory period of ONE MONTH or THIRTY DAYS from the mailing date of this letter, whichever is longer, to submit a complete reply. This shortened statutory period supersedes the time period set in the prior Office action. This time period may be extended pursuant to 37 CFR 1.136(a). If a notice of appeal and the fee set forth in 37 CFR 1.17(e) were filed prior to or with the payment of the fee set forth in 37 CFR 1.17(r), the payment of the fee set forth in 37 CFR 1.17(r) by applicant is construed as a request to dismiss the appeal and to continue prosecution under 37 CFR 1.129(a). The appeal stands dismissed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CARALYNNE HELM whose telephone number is (571)270-3506. The examiner can normally be reached on Monday through Friday 8-5 (EDT).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Caralynne Helm/  
Examiner, Art Unit 1615

/MP WOODWARD/  
Supervisory Patent Examiner, Art Unit 1615